Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivir has reported that Presidio Pharmaceuticals has elected to return the license rights to the HIV nucleoside reverse transcriptase inhibitor MIV-310, enabling Medivir to transfer the full license to the compound and intellectual property to Beijing Mefuvir Medicinal Technology, which will develop MIV-310 for therapeutic use against HIV.
Subscribe to our email newsletter
Under the new terms for MIV-310, Mefuvir will finance the clinical development towards registration in Asia. Mefuvir has the marketing rights in Asia except Japan. Medivir retains the marketing rights in the rest of the world.
When Medivir and Presidio entered a licensing agreement in December 2006 the total deal value amounted to $75.25m. Due to the transfer of MIV-310, the terms with Presidio have been adjusted, leaving $52.25m in milestones for the development of the pre-clinical HIV project MIV-410 (PPI-801/802), which is not affected by the MIV-310 license transfer.
Zhang Wenyao, chaiman of the board, Tianjin Human-Care Latex and Beijing Mefuvir Medicinal Science, said: “The possibility to use combination tablets with MIV-310 and AZT is of great interest for its convenience of dosing and low risk for resistance development.”